Department of Infectious Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, China.
Can J Gastroenterol Hepatol. 2017;2017:8467192. doi: 10.1155/2017/8467192. Epub 2017 Feb 21.
Metabolomics as the new omics technique develops after genomics, transcriptomics, and proteomics and has rapid development at present. Liver diseases are worldwide public health problems. In China, chronic hepatitis B and its secondary diseases are the common liver diseases. They can be diagnosed by the combination of history, virology, liver function, and medical imaging. However, some patients seldom have relevant physical examination, so the diagnosis may be delayed. Many other liver diseases, such as drug-induced liver injury (DILI), alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD), and autoimmune liver diseases, still do not have definite diagnostic markers; the diagnosis consists of history, medical imaging, and the relevant score. As a result, the clinical work becomes very complex. So it has broad prospects to explore the specific and sensitive biomarkers of liver diseases with metabolomics. In this paper, there are several summaries which are related to the current research progress and application of metabolomics on biomarkers of liver diseases.
代谢组学是继基因组学、转录组学和蛋白质组学之后发展起来的新组学技术，目前发展迅速。肝脏疾病是全球性的公共卫生问题。在中国，慢性乙型肝炎及其继发疾病是常见的肝脏疾病。它们可以通过病史、病毒学、肝功能和医学影像学相结合来诊断。然而，有些患者很少进行相关体检，因此可能会延误诊断。许多其他肝脏疾病，如药物性肝损伤（DILI）、酒精性肝病（ALD）和非酒精性脂肪性肝病（NAFLD）以及自身免疫性肝病，仍然没有明确的诊断标志物；诊断包括病史、医学影像学和相关评分。因此，临床工作变得非常复杂。因此，利用代谢组学探索肝脏疾病特异性和敏感性生物标志物具有广阔的前景。本文对代谢组学在肝脏疾病生物标志物方面的研究进展和应用进行了综述。
